Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology.

@article{Marchetti2013RecommendationsFT,
  title={Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology.},
  author={Antonio Marchetti and Andrea Ardizzoni and Mauro Papotti and Lucio Crin{\`o} and Giulio Rossi and Cesare Gridelli and Massimo Barberis and Eugenio Maiorano and Nicola Normanno and Gian Luigi Taddei and Giorgio Scagliotti and Claudio Clemente and Carmine Pinto},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2013},
  volume={8 3},
  pages={
          352-8
        }
}
INTRODUCTION Recent clinical trials led to the approval of crizotinib (PF-02341066; Pfizer) by the U.S. Food and Drug Administration for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients whose tumors are positive for anaplastic lymphoma kinase (ALK) alterations. The European Medicines Agency accepted the regulatory submission of crizotinib for the treatment of these patients. Therefore, ALK gene testing has become mandatory to choose the most… CONTINUE READING
Tweets
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 12 citations